Reimbursed Care Access in Nauru

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of licensed psilocybin medical programs or reimbursement pathways in Nauru; access would be limited to authorised international clinical research if any such trials were run or to special import/compassionate-use arrangements approved by the Ministry of Health and Medical Services. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no public indications that MDMA‑assisted therapy is authorized, reimbursed, or available in Nauru; access would be constrained to approved clinical trials or exceptional import approvals by the Ministry of Health. #.

Esketamine (intranasal Spravato®) is a novel, regulated antidepressant in some high‑income jurisdictions, but there is no publicly available evidence that esketamine has been registered, funded, or reimbursed for routine commercial use in Nauru. Nauru’s public healthcare services are limited and there is no record of a national reimbursement pathway for esketamine; if required for an individual patient, access would likely depend on import approval and Ministry of Health authorisation or treatment overseas. The country’s small health system relies on basic acute care and occasional medical evacuation to larger centers for specialised care, making routine local provision and reimbursement of esketamine unlikely. #.

Ketamine is an established injectable anaesthetic and analgesic widely recognised on the WHO Model List of Essential Medicines for anaesthesia and procedural sedation, and it is commonly used worldwide in acute care and surgical settings. #.

In Nauru specifically, health services are basic and managed through the Ministry of Health and Medical Services; given the WHO essential‑medicine status of ketamine and the need for basic anaesthetic agents in small island hospitals, ketamine would be the only compound from this list with a routine, medically accepted role (primarily as an anaesthetic/analgesic) and likely to be stocked for emergency and surgical use. However, there is no publicly available evidence of a reimbursed, licensed ketamine‑based mental‑health program (e.g., ketamine infusion clinics for depression) in Nauru, and any off‑label psychiatric use would be ad hoc, clinician‑driven, and depend on import/approval processes overseen by the Ministry of Health and Medical Services. For context on Nauru’s limited healthcare capacity and likely reliance on essential medicines and overseas referral for specialty care, see the UK travel health brief. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of DMT‑based clinical programs, licensing, or reimbursement in Nauru. Access would be limited to authorised clinical research or exceptional import approvals. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No national medical programs or reimbursement frameworks for 5‑MeO‑DMT are evident for Nauru; access would be limited to approved research or exceptional import authorisations by health authorities. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of authorised ibogaine treatment or reimbursement in Nauru; any access would require specific Ministry of Health approval for research or compassionate use. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Traditional or ritual ayahuasca use and reimbursement are not recognised in Nauru’s health system; importation or clinical use would require explicit regulatory approval. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of mescaline being authorised or reimbursed for medical purposes in Nauru; access would be limited to formal research approvals if pursued. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of any medical or reimbursed access to 2C‑series compounds in Nauru; possession or supply would be subject to criminal controls. #.